Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. [electronic resource]
Producer: 20150703Description: 2244-2251 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug-Related Side Effects and Adverse Reactions -- pathology
- Female
- Humans
- Middle Aged
- Naphthalenes -- analysis
- Neoplasms -- classification
- Neovascularization, Pathologic -- drug therapy
- Protein Kinase Inhibitors -- administration & dosage
- Quinolines -- analysis
- Receptor, Fibroblast Growth Factor, Type 1 -- antagonists & inhibitors
- Receptor, Fibroblast Growth Factor, Type 2 -- antagonists & inhibitors
- Receptors, Platelet-Derived Growth Factor
- Vascular Endothelial Growth Factor Receptor-1 -- antagonists & inhibitors
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
There are no comments on this title.
Log in to your account to post a comment.